Overview
Project Summary
Recent immunotherapeutic strategies, such as immune checkpoint inhibitors or CAR T cells, have revolutionized cancer therapy. With this project, we propose to discover new targets for cancer immunotherapy mediated by cDC1s using a completely new approach based on dendritic cells reprogramming. Our group has recently described the reprogramming of mouse and human fibroblasts into cDC1s with PU.1, IRF8 and BATF3. We now propose to unravel the mechanisms involved in cDC1 specification and cross-presentation ability using cDC1 reprogramming.
Main Goals
To identify novel druggable targets and validate small molecule inhibitors that can be developed as novel immunotherapeutic agents.
Coordination
Internal Team
Funding
Project Details
Project Code
2022.02338.PTDC
Region
Center
Start Date
2023-03-01
End Date
2026-02-28
Total Cost
249999.59€
